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In the growing field of biotechnology research and development, a new phenomenon 
is emerging – the strategic use of race as a genetic category to obtain patent protection 
and drug approval. The imbrication of race in the field of patent law as an adjunct to 
biotechnological inventions is producing new racialized spaces of intellectual 
property that may have profound implications for broader social understandings and 
mobilizations of race. When the federal government grants a patent to an invention 
that is based on an asserted or implied genetic basis for a particular racial group, it 
gives the imprimatur of the federal government to the construction of race as genetic. 
Moreover, once granted, such patents may provide the basis for similarly race-based 
clinical trial designs, drug development, capital raising and marketing strategies that 
carry the construction of race as genetic out to ever widening and consequential 
segments of society. 
 
A dramatic rise in the use of race in biotechnology patents since the completion of the 
first draft of the human genome in 2000 indicates that researchers and affiliated 
commercial enterprises are coming to see such social categories as presenting 
opportunities for gaining, extending, or protecting monopoly market protection for an 
array of products and services. The commercial mobilization of race and ethnicity is 
not merely coincidental with the proliferation of new genetic knowledge. Rather, 
federal initiatives have played a central role in producing, classifying, and 
disseminating human genetic information. Once race is conceptualized in relation to 
biotechnology products, the patent system itself provides incentives for using race and 
ethnicity in order to maximize patent scope, duration, and viability. Federal 
initiatives, guidelines, and approvals thus provide specific, targeted incentives to see 
and use race and ethnicity in relation to biotechnological innovation in a manner that 
promotes, indeed rewards, the reification of race as a genetic category. 
 
Few areas of the law currently are as fully engaged in a pervasive management of 
genetic material and information as intellectual property law. Patent law and genetics, 
however, while much examined, are generally explored in terms of how best to 
promote the efficient production and exploitation of genetic information. While the 
ethical implications of patenting human genetic material have been explored at length, 
little attention has been given to the ways in which social categories of race and 
ethnicity are increasingly being mobilized in the context of biotechnology patents. 
 
A “product of nature” cannot be patented. To be rendered patentable, it must be 
“purified and isolated” through human interventions to produce a substance that does 
not otherwise exist. Historically, this involved complex chemicals such as 
adrenaline.3 In the genomic era, however, it has come to encompass engineered 
complementary DNA (cDNA). DNA as found in nature contains both nucleotide 
sequences that code for producing proteins (exons) and sequences that do not code fo
proteins (introns). cDNA is synthesized in vitro by using an enzyme (reverse 
transcriptase) that produces a molecule containing only exons. While clearly scient
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it comes to granting a patent.4 The U.S. Patent and Trademark Office (PTO) h
asserted that, “the inventor’s discovery of a gene can be the basis for a patent of the 
genetic composition isolated from its natural state and processed through purifying 























it into a natural construct in order to gain patent protection 
and market advantage. 
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Sheila Jasanoff observes that “biotechnology […] renders continually problematic 
boundary between the natural and the unnatural”.6 The authoritative discourses of 
science and law, however, are rendered precarious by such uncertainty. Those seeking
the legal recognition of patentability for biotechnological achievements work hard 
resolidify and render apparently unproblematic the boundary between natural and 
unnatural. Thus, the PTO recognizes arguments that scientific intervention creates a 
patentable object by severing it from its “natural associations”7. The PTO constructs
cDNA as isolated, not only in the sense of separating exons from introns, but more 
powerfully, in the sense of separating the genetic material itself from nature. This is 
not a scientific process but a legal one. The scientist may create cDNA but the PTO 
draws the line between nature and artifice. Similarly, purification involves strippi
the genetic material of
a
 
This paper will explore how the rise of racial patents inverts this traditional dynamic. 
Patents have long been premised on a legal recognition of how human intervention 
may take a product out of nature and into culture. In contrast, race enters the world o
biotechnology as a social construct. It serves as an admitted surrogate for presu
underlying genetic variations in particular populations. In the patent and drug 
approval process necessary to bring the drug to market, race is implicitly recoded as a
genetic category. The patent process takes race as a social category and recodes it as 
“natural” by according it legal force as a component of a biotechno
L
 
The paper begins with a consideration of diverse federal mandates that structure the 
collection, classification, and circulation of data about both social categories of
and genetic categories of population. When brought together in the context of 
biotechnology research and product development, these diverse federal classificatory
schemes become easily entangled and conflated, providing a structural incentive
reifying race as genetic. It proceeds to a discussion of BiDil, the first drug ever 
approved by the Food and Drug Administration (FDA) with a race specific indication
– for the treatment of heart failure in African-Americans. It argues that the dynamic 
whereby commercial and legal considerations drove the development of BiDil is a 
portent of further commercial exploitation of race in biotechnology. The paper then 
moves on to a detailed analysis of the new racial patents in biotechnology exploring
the myriad ways in which the legal imperatives of patent law are appropriating the 
language of science and medicine to imbue products with new commodity val
reifying race as genetic. It concludes with the observation that biotechnology 
corporations are mining the raw material of race as a social category and using the 
patent process to refine 
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The Impact of Federal Schemes of Classification 
 
The racialization of patent law can only fully be understood when viewed in relation 
to broader federal initiatives that shape the production and use of racial8 categories in 
biomedical research. Prominent among these are a wide array of federal mandates that 
dictate the characterization and application of genetically-based biomedical 
interventions, such as pharmaceuticals and diagnostic tests, in relation to socially 
defined categories of race. Key federal mandates include: the National Institutes of 
Health (NIH) Revitalization Act of 1993, which directed the NIH to establish 
guidelines for inclusion of women and minorities in clinical research9; the Food and 
Drug Modernization Act of 1997, which, in the context of drug development, directed 
that “the Secretary [of Health and Human Services] shall, in consultation with the 
Director of the NIH and with representatives of the drug manufacturing industry, 
review and develop guidance, as appropriate, on the inclusion of women and 
minorities in clinical trials”, and two subsequent FDA “Guidances for Industry”. The 
first, a 1999 guidance titled “Population Pharmacokinetics”, made recommendations 
on the use of population pharmacokinetics in the drug development process to help 
identify differences in drug safety and efficacy among population subgroups, 
including race and ethnicity10; and the second, a 2005 guidance entitled “Collection of 
Race and Ethnicity Data in Clinical Trials”,  which recommends a standardized 
approach for collecting and reporting race and ethnicity information in clinical trials 
that produce data for applications to the FDA for drug approval. 
11
 
Underlying the standardization of data collection in all of these mandates is the Office 
of Management and Budget’s Revised Directive 15 on “Standards for Maintaining, 
Collecting, and Presenting Federal Data on Race and Ethnicity”.12 The standards were 
developed “to provide a common language for uniformity and comparability in the 
collection and use of data on race and ethnicity by Federal agencies”. The standards 
set forth the following basic racial categories for organizing such data: American 
Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or 
Other Pacific Islander, and White. There are two categories for data on ethnicity: 
“Hispanic or Latino”, and “Not Hispanic or Latino”.13 Sociologist Michael Omi 
observes, “Directive 15 has become the de facto standard for state and local agencies, 
the private and nonprofit sectors, and the research community”.14 This dynamic 
reinforces what Omi has characterized as an “interesting dilemma” facing scientists in 
the United States: “On the one hand,” Omi asserts, “scientists routinely use racial 
categories in their research and regularly make comparisons between races with 
respect to health. […] On the other hand, many scientists feel that racial 
classifications are meaningless and unscientific”.15 
 
Producing and Organizing Genetic Information: Federally Sponsored Genetic 
Data-bases 
 
This dilemma is likely to become ever more problematic when biomedical researchers 
and clinicians are using the social categories of race mandated by Directive 15 
alongside of purportedly genetic population groupings produced and organized by 
federally sponsored genomic initiatives. As genetic research has grown over the past 
three decades, the federal government has sponsored or co-sponsored an array of data 
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banks that collect, store, and classify genetic information for use by biomedical 
researchers. Such data banks include the National Institute of General Medical 
Sciences’ (NIGMS)-Coriell Human Genetic Variation Collections, the National 
Human Genome Institute’s DNA Polymorphism Discovery Resource (PDR), the 
National Center for Biotechnology Information’s dbSNP data-base, and the 
International Haplotype Map Project (also known as the HapMap). Each of these 
data-bases organize genetic information into highly problematic population groupings 
that have been taken up and used by researchers as correlates for or equivalents of 
racial categories. Overarching these collections is a repository maintained by the 
federal government’s National Center for Biotechnology Information,16 known as 
GenBank, which contains a web-based annotated collection of all publicly available 
DNA sequences. These data-bases are powerful, not only because of the categories 
they use to organize genetic information internally, but also because as examples of 
authoritative scientific knowledge, they provide working models of acceptable 
schemes of categorization by which any genetic data may be organized, wherever 
obtained or stored. 
 
These federal data-bases mix and match crude categories that variously employ racial 
and ethnic constructs (eg, U.S. Caucasians, African Americans, and Hispanics), 
geographic constructs (eg, North Africa, East Africa), political nation states (eg, 
Russia and Satellite republics), mixes of geography and nation states (eg, Sub-
Saharan Nations bordering the Atlantic North of the Congo River); and mixes of all 
three (eg, “All samples north of Tropic of Cancer. This would include defined 
samples of U.S. Caucasians, African Americans and Hispanics.”) As biomedical 
researchers mine such data, they are accessing and organizing it in terms that 
juxtapose or directly classify genetic data in terms of race, ethnicity, nation, and/or 
geography. When used in studies or trials covered by federal mandates, the diverse 
and sometimes contradictory population classifications employed variously by the 
NIGMS, the PDR and dbSNP data-bases cry out to be simplified and reclassified in 
terms of the basic OMB 15 categories of race and ethnicity. Thus, for example, a 
locally specific genetic sample, originally designated as from an individual in Tokyo, 
Japan, is likely in subsequent practice to be conflated into the overarching category of 
“Asian.” 
 
All of these genetic data-bases are technologies of classification. Systems of 
classification, however, are artifacts that embody ethical choices. As Geoffrey 
Bowker and Susan Star note, “each standard and category valorizes some point of 
view and silences another. This is not inherently a bad thing – indeed it is inescapable. 
But it is an ethical choice, and as such it is dangerous – not bad, but dangerous”.17 In 
the realm of genetics, where such systems address the human body, new biologically 
based categories can profoundly affect people’s identities, aspirations, and dignity. 
Genetic classification is powerful but it is also dangerous because it involves 
biological categories that may be confused and conflated with race. Any resulting 
reification of social categories of race as biological constructs risks new forms of 
exclusion and stigma.18 
 
Bowker and Star argue that “politically and socially charged agendas are often first 
presented as purely technical and they are difficult even to see. As layers of 
classification system become enfolded into a working infrastructure, the original 
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political intervention becomes more and more firmly entrenched. In many cases, this 
leads to a naturalization of the political category. […] It becomes taken for granted”.19 
Genetic data-bases and OMB Directive 15 are seemingly “technical” methods of 
categorization, but such apparent neutrality is precisely what drives and lends the aura 
of legitimacy to the casual and often reflexive conflation of race and genetics in a 
variety of biomedical contexts. 
 
These federal mandates have a profound effect upon the use of racial categories in 
biomedical research, clinical practice, product development, and health policy. At the 
most basic level, they create incentives to introduce race into biomedical contexts, 
regardless of their relevance. Once introduced, racial categories can take on a life of 
their own and become exploited in new and unanticipated ways, with unforeseen and 
potentially harmful consequences. 
 
BiDil: Portent of Things to Come 
 
This has already begun to happen. In June, 2005, a drug called “BiDil” became the 
first drug ever approved by the FDA with a race specific indication: to treat heart 
failure in African Americans.20 Underlying the New Drug Application (NDA) 
submitted for this drug to the FDA is a race–specific methods patent: to use the drug 
for treatment of heart failure in an African American patient. The patent is premised 
on underlying assumptions regarding race and the genetic basis of heart disease. By 
granting such a patent, the Patent and Trademark Office (PTO) is giving the 
imprimatur of the federal government to the use of race as a genetic category.21 
BiDil’s history is complex and has been explored in detail.22 It reveals a story of how 
race and ethnicity were exploited in conjunction with patent law and the drug 
approval process to bring a new drug to market. In short, BiDil became a racially 
marked drug more because of law and commerce than because of medical evidence.23 
 
All indications seem to show that the drug is highly effective at treating heart failure. 
The FDA approval, however, was based on results from A-HeFT, the African-
American Heart Failure Trial, that were published the previous November in the New 
England Journal of Medicine.24 The trial design, approved by the FDA, was itself 
path-breaking because it included only self-identified African Americans. The results 
therefore give the impression that BiDil works only in African Americans. This is 
clearly not the case. The trial investigators themselves concede that BiDil will work in 
people regardless of race. Without a comparison population, the investigators cannot 
even claim that the drug works differently in African Americans than in any other 
group. Nonetheless, NitroMed, the corporate sponsor of BiDil, applied for and 
received FDA approval for the drug with a race-specific indication to treat heart 
failure only in African Americans. Pervasive media coverage of the announcement of 
the results and the FDA approval has also focused on the racial-specificity of the 
drug, often explicitly claiming that this shows race is genetic.25 Thus, for example, in 
addition to casual references to a race-specific genetic basis for BiDil’s efficacy in the 
popular media, articles published in such scientific and professional journals such as 
Genome Biology the British Medical Journal, and Health Affairs have also incorrectly 
asserted a genetic variation more prevalent in self-identified African-Americans to 
underlie BiDil’s efficacy.26 
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BiDil is the prototypical example of patenting race in a genomic age. Underlying the 
trial design is a race-specific patent that is premised on a genetic conception of race. 
The PTO issued the patent on October 15, 2002. 27 It confers intellectual property 
protection for the method of using the drug to treat heart failure in African Americans 
until 2020. This is thirteen years longer than a previous patent issued in 1987 to the 
same inventor for the same method of using the same drug in the general population 
without regard to race. In this case, bringing race into the patent system allowed the 
inventor to gain a substantial extension of his intellectual property monopoly. With a 
projected annual revenue stream of one to three billion dollars, the additional thirteen 
years amounts to a tremendous windfall for NitroMed.28 BiDil’s race-specific patent 
provided the underlying support that drove NitroMed’s subsequent development of a 
race-specific trial design, its campaign to raise capital (first through private venture 
funding and later through a public offering of stock in 2004), the approach to the FDA 
for race-specific approval, and its massive marketing campaign to third party payers, 
individual doctors, and the public at large. But the broader implications of using race 
to obtain patent protection and drug approval have only begun to be explored.  
 
Both the patent and the drug trial for BiDil explicitly relate their race-specific design 
to a search for genetic markers underlying the disease.29 On the one hand, this reflects 
an approach, largely sanctioned by many in the field of pharmacogenomics, of using 
race instrumentally as a surrogate to get at underlying genetic variation that could be 
ultimately identified without reference to race. On the other hand, for the foreseeable 
future, it presents the immediate reality of race being used as a quasi-genetic category 
to obtain patents and drug approval. 
 
Is BiDil an anomaly? Discussions of similar race-specific trials for the cancer drug 
Iressa and the statin Crestor, among others, would seem to indicate that BiDil is 
ushering in a new era of race-based medicine.30 As Tate and Goldstein observe, there 
are already numerous drugs on the market that claim to have shown differential 
efficacy among different races.31 While they note that most of these claims are not 
well-supported by the evidence, this merely underlines the importance of examining 
more closely what other factors may be providing incentives to see race as relevant. 
Similar dynamics are at work in Europe. In June 2005, over the strenuous objections 
of the European Council of Human Genetics, the European Patent and Trademark 
Office upheld a patent owned by Myriad Genetics relating to testing for the BRCA2 
genetic mutation “for diagnosing a predisposition to breast cancer in Ashkenazi 
Jewish women”.32 Opponents of the patent noted that the test is currently available 
from other sources for all women regardless of ethnic or religious background. As a 
practical matter, this new patent means that individuals identified as Ashkenazi Jews 
will either have to pay a premium for the test or deny their identity. As with BiDil, 
here Myriad apparently is marking an ethnic group as genetically distinct primarily in 
order to extend patent protection – with potentially profound consequences.33 
 
A recent report from the Royal Society in the United Kingdom asserted that the 
promise of truly individualized pharmacogenomic therapies remains decades away.34 
In the gap between present reality and future promises there may be various strategies 
for capitalizing on emerging genetic knowledge relating to drug response and 
efficacy. Targeting a racial audience presents a particularly attractive interim option 
because at this point the technology and resources do not exist to scan efficiently 
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every individual’s genetic profile. Instead businesses may market the product to a 
particular social group that is hypothesized to have a higher prevalence of a relevant 
genetic variation. Patent protection provides an essential underpinning for such 
commercial ventures. As race is becoming more relevant to marketing drugs, it is 
becoming a salient component of underlying biotechnology patents. 
 
Patent law provides a focused and dynamic site in which to identify and examine 
emerging examples of race and genetics being mobilized in tandem to serve both 
biomedical and commercial projects. As researchers derive new inventions based on 
mining existing genetic data-bases, patent law provides powerful commercial 
incentives to conflate race and genetics. In approving such uses, the United States 
Patent Office gives the imprimatur of the federal government to the reification of race 
and ethnicity as genetic categories. It also puts the weight of federal authority behind 
such uses by placing the burden of disputing such reification upon those (if any) who 
have the time, money, expertise and inclination to challenge the patents. 
 
The Rise of Racial Patents 
 
A modern patent is a “government issued grant which confers upon the patent owner 
the right to exclude others from ‘making, using, offering for sale, or selling the 
invention throughout the United States or importing the invention into the United 
States’ for a period of 20 years ending from the filing date of the application”.35 This 
authority derives from the United States Constitution, Article 1, section 8, which 
states: “The Congress shall have power to […] promote the progress of science and 
useful arts, by securing for limited times to authors and inventors the exclusive rights 
to their respective writings and discoveries.” All patent applications must meet several 
statutory requirements. The most prominent of these are known as “useful[ness]” (or 
utility) (35 U.S.C. § 101), “novelty” (35 U.S.C. §102), “non-obvious[ness]” (35 
U.S.C. § 103) and “specification” (35 U.S.C. § 112). The usefulness, or utility, 
requirement can be met by a showing that the claimed invention has a specific, 
substantial, and credible utility. Specificity requires the use to be specific to the 
character of the claimed subject matter. The novelty requirement is met if the 
invention is not “anticipated” (described in its relevant particulars) in a single 
reference of “prior art” (eg, another patent or a published scholarly paper). The non-
obviousness requirement is met if “the differences between the subject matter sought 
to be patented and the prior are such that the subject matter as a whole” would not be 
perceived as obvious to a “Person Having Ordinary Skill in the Art” (known in patent 
lingo as a PHOSITA, 35 U.S.C. § 103[a]). Specificity requires a written description of 
the invention that is adequate to enable a PHOSITA to make and use the invention.36 
 
Patent law is premised on legally constructing a divide between nature and society. In 
affirming the patentability of a genetically engineered bacterium, the U.S. Supreme 
Court asserted that patentable subject matter included “anything under the sun made 
by man”.37 As discussed above, the U.S. patent system recognizes that genes can be 
patented to the extent that the genetic material is legally understood as having been 
isolated and purified in a manner that effectively takes it out of the realm of nature 
and into the realm of society as an artifact of human creation.38 
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Ironically, and ominously, when race is used in a gene-related patent a reverse of this 
transformation may occur. In such patents, race begins as a social category, often 
derived from categories specified by OMB directives. Biomedical professionals may 
link race to genetic categories with the goal of somehow facilitating their research or 
practice. But when a gene-related race-identified patent issues, it legally marks race 
as, at least in part, a genetic category – ie, the patent takes the social category of race 
and transforms it into a “natural” category grounded in genetics. DNA, however, is 
not patented simply to claim title to a nucleotide sequence. It is patented in order 
ultimately to bring some DNA-related product to market. When that product is a drug, 
federal guidelines mandate that clinical trial data be collected with reference to social 
categories of race and ethnicity that are promulgated by the Office of Management 
and Budget.39 
 
Patent law is supposed to promote the invention of new and useful products. In recent 
biotechnology patents race and ethnicity are being exploited in new ways that do not 
spur the invention of a new product, but rather the reinvention of an existing product 
as racial or ethnic. In so doing, patent law both racializes the space of intellectual 
property, transforming it into a terrain for the re-naturalization of race as some sort of 
“objective” biological category, and commodifies race and ethnicity as goods to be 
patented and subjected to the dictates of market forces. 
 
A review of “claims” and “abstract” sections of gene-related patents and patent 
applications40 filed since 1976 indicates a significant trend toward using race in gene-
related patents with a marked increase in just the past few years. This rise is clearly 
coincident both with an increase in genetic information being produced through the 
federally sponsored Human Genome and HapMap Projects, and also with rising 
federal emphases on requiring the use of racial and ethnic categories in the collection 
of data relating to clinical trials and drug applications. A typical patent is divided into 
several sections. The claims section presents a primary focus for investigation because 
it is the legal heart of a patent. The claims specify the legally operative scope of the 
patent, defining the formal legal “metes and bounds” of the territory covered by an 
invention.41 The abstract is the basic summary presentation of the central purpose of 
the patent. Other sections typically include a “background” or “description of 
invention,” plus drawings or other technical support data.  A review of the claims or 
abstract sections of patents that employ OMB 15 categories of race and ethnicity42 in 
a manner that implies or asserts a genetic component to or basis for race43 reveals that 
in the four years between 2001 and 2005, there was a more than a five-fold increase in 
the use of racial and ethnic categories in gene-related patent applications over existing 
patents issued in the twenty-nine years since 1976 – from 12 to 65 (see Table I). 
When updated through August 2007 the totals rise to 197 – allowing for multiple 
references this includes 27 distinct patents and 100 distinct pending patent 
applications (See Table II). 
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Issued patents: Category 1976-1997 1998-2005 
Patent applications 
filed 2001-05 
Race 0 2 15 
Ethnic 0 0 2 
African-American / 
Black 
0 4 11 
Alaska Native 0 0 0 
Asian 0 0 13 
Caucasian / White 0 6 18 
Hispanic / Latino 0 0 3 
Native American 0 0 2 
Pacific Islander 0 0 1 
Total 0 12 65 
 
Table I. The Rise of Racial Patents - 2005 
 
 
Issued patents: Category 1976-1997 1998-2007 
Patent applications 
filed 2001-07 
Race 0 2 15 
Ethnic 0 9 39 
African-American / 
Black 
0 7 14 
Alaska Native 0 0 0 
Asian 0 1 17 
Caucasian / White 0 6 44 
Hispanic / Latino 0 3 7 
Native American 0 1 14 
Pacific Islander 0 0 1 
Total 0 29 154 
 
Table II. The Rise of Racial Patents – 2007 
 
 
Category Patent Applications filed 2001-05 
Patent Applications 
filed 2001-07 
Race 15 15 
Ethnic 2 39 
African-American / Black 11 14 
Alaska Native 0 0 
Asian 13 17 
Caucasian / White 18 44 
Hispanic / Latino 3 7 
Native American 2 14 
Pacific Islander 1 1 
Total 65 154 
 
Table III. The Rise of Racial Patents: 2005-2007 
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This rise is not because race has not previously been used in biomedical research, but 
rather because it is taking on increasing significance in the commercial world of 
biotechnology patenting. A comparison of racial patents between 2005 and 2007 
(Table III) indicates a dramatic rise in the use of the terms “ethnic” (from 2 to 39) and 
“Caucasian” (from 18 to 44) that is suggestive of certain emerging conceptualizations 
of race at work in biotechnology patenting. First, the embrace of the term “ethnic” 
seems to reflect a broader social move to replace the politically charged terminology 
of race with the purportedly more neutral concept of ethnicity. Second, as discussed 
below, the rising use of the term Caucasian may reflect an understanding that first 
world Caucasian populations are where the money is or, more pragmatically, a 
recognition that the hitherto largely unmarked category of Caucasians actually 
constitutes a “race” that can be made the subject of a patent claim. 
 
A reading of the entire text of these identified patents and applications indicates a 
remarkable trend toward the increasing use of racial and ethnic categories in relation 
to patenting gene-related biomedical innovations. Of the twelve granted patents 
identified, the earliest specifies the use of the term “Caucasian”. It relates to 
diagnostic testing for the BRCA1 genetic mutation for breast cancer and was granted 
only in 1998. Two of the remaining patents concern the drug BiDil, discussed above, 
the first of which was granted in 2002. In the four years since 2001, there has been 
close to a five-fold increase in the use of racial and ethnic categories in gene-related 
patent applications over existing patents issued in the twenty-nine years since 1976. 
This is not because race has not previously been used in biomedical research, but 
rather because it is taking on increasing significance in the commercial world of 
biotechnology patenting. While there are some overlapping references (ie, patents that 
use more than one OMB category) the trend remains powerful and clearly parallels 
the availability of vast new amounts of genetic information being produced and 
classified in federally sponsored data-bases. For example, on 20 November 2003, 
Tony Frudakis of DNAPrint Genomics filed an application “Compositions and 
methods for inferring a response to statin,” which explicitly bases some of its race-
specific claims on samples taken from the Polymorphism Discovery Resource.44 The 
application looks at allele frequencies in a “Caucasian” population to infer a 
differential race-specific response to statin—a blockbuster class of cholesterol-
lowering drugs. 
 
How exactly is race being used in these patents? At the most pragmatic level, many 
patent applicants appear to be invoking race in a strategically defensive manner to 
provide added protection against possible patent challenges. The structure of a typical 
claims section of a patent begins with claim #1 being as broad as possible. Successive 
claims generally provide narrower and narrower focus to the territory covered by the 
patent. The idea here is that if the broadest claim is struck down by the patent 
examiner or a subsequent challenge, the narrower claims may still survive. Patent 
claims are thus structured something like a medieval castle, with an outer ring 
encompassing the most territory with successively smaller rings providing additional 
layers of protection back to the core area of the castle keep. 
 
A patent application for “Detection of susceptibility to autoimmune diseases”, filed on 
1 July 2004, exemplifies the use of concentric rings of race to provide maximum 
protection for its claims.45 Its first three claims are as follows: 
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1. A method for determining an individual's risk for type 1 diabetes 
comprising: detecting the presence of a type 1 diabetes-associated 
class I HLA-C allele in a nucleic acid sample of the individual, 
wherein the presence of said allele indicates the individual's risk for 
type 1 diabetes.  
2. The method of claim 1, wherein the individual is of Asian descent.  
3. The method of claim 1, wherein the individual is of Filipino 
descent. [Emphasis added] 
Claim 1 is not race-specific, referring only to an “individual’s” risk. 
Claim 2 takes a smaller subset of humanity which it marks as 
“Asian.” Claim 3 takes yet a smaller sub-set of the group “Asian” 
which it marks as “Filipino.” In each case the categories are clearly 
linked to genetic alleles, forcefully implying a genetic basis to the 
specific racial groups. 
 
The logic of connecting race and genetics in this context, however, is not driven by 
science so much as by the commercial imperatives of patent law. The body of the 
patent, which generally describes the invention and its background, reviews the 
scientific literature underlying the claims. In this, less legally potent portion of the 
patent, the terms “Asian” and “Filipino” are invoked in terms of variable distributions 
of HLA allele frequency across populations. The “description” section of the patent 
compares, in particular, the incidence of type 1 diabetes in Japan and China to 
populations in the U.S. and Europe. It goes on to discuss the frequency in the 
Philippines as well. In this context, the boundaries of the racial or national categories 
being employed are not hard and fast. It is not that “Asians” per se have different 
genes from “Europeans.” Rather, it notes that there appear to be variable allele 
frequency and disease incidence across certain populations. Such uses of population 
categories may remain problematic in their broad generality but they are not 
essentially genetically reductive because they deal with relative allele frequencies that 
are acknowledged to exist across populations. In contrast, in the “summary of the 
invention” section, the application states that, “The individual can belong to any race 
or population. In one embodiment, the individual is an Asian, preferably a Filipino.” 
An embodiment refers to the formal metes and bounds of the patent delineated by the 
claims. Like the claims themselves, the summary sets forth definitively bounded 
categories that mark specified races as (genetically) distinct. The legal and 
commercial imperatives of effective patenting have here promoted the transmutation 
of variable genetic frequencies across populations that nonetheless all share common 
alleles, into bounded genetic categories that are marked as distinct and functionally 
different. 
 
Also of note is that the category “Asian” is apparently derived from studies only of 
Japanese and Chinese subjects, thus conflating two national populations with an entire 
continent. Moreover, there are separate claims regarding Asians and Filipinos, 
implying some distinctive genetic basis to Filipinos that distinguishes them from other 
populations encompassed by the larger category “Asian.” This separate claim is 
apparently based on a study of ninety Filipinos discussed in the body of the patent. 
 
Many of the patents invoke race when the inventors construct a perceived departure 
from an unstated White norm (eg, of disease or allele prevalence) in a non-White 
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group. In such contexts, the term “individual” or “human” implicitly stands for 
“White” in the claims. As Rene Bowser notes: 
 
In nearly all racialized research published in the United States, the 
comparison group has been the majority (White) population. Far 
from being a neutral category, this approach consolidates Whites as 
the group with which all "others" should be compared; it also 
disregards research that demonstrates the value of studying 
variations in health among, say, Blacks, as opposed to always 
comparing them with White Americans. The norm in racialized 
research is and has always been an unspoken but taken-for-granted 
White norm.46 
 
This is particularly evident in one of the BiDil patents. Issued on 15 October 2002, 
patent #6,465,463 refers in claim 1 to “A method of reducing mortality associated 
with heart failure […] in a black patient.” Claim 2 goes on to specify, “the method of 
claim 1, wherein the black patient has a less active rennin-angiotensin system relative 
to a white patient.” Here White is the norm from which Black deviates. As elaborated 
in the “Background of the Invention,” the patent goes on to assert that “heart failure in 
black patients has been associated with a poorer prognosis than in white patients. In 
diseases such as hypertension, Blacks exhibit pathophysiologic differences and 
respond differently to some therapies than Whites.” The body of the patent thus 
pathologizes Blackness as both biologically distinct from and less healthy than the 
White norm. 
 
Another typical example of the unstated White norm may be seen in a patent 
application for a “Method of identifying a polymorphism in CYP2D6”, filed 11 
November 2003.47 (CYP2D6 is of particular interest to pharmaceutical corporations 
because it is involved with drug metabolism.) The first Claim specifies “A method of 
determining a cytochrome P-450 2D6 genotype of an individual […]” Claim 12 
specifies “The method, as claimed in claim 1, wherein said individual is Asian.” The 
focus on an “Asian” individual is explained in the “Background to the Invention” 
which notes “differences between Caucasians and Asians are explained by an unequal 
distribution of CYP2D6 alleles”. The application asserted different population-based 
allelic frequencies between Caucasians and Asians; but this is a two-sided difference -
- that is, each differs from the other. But it is only Asians that are specified in the 
Claims as a sub-set of the broader term individual. Caucasians logically could be but 
here are not similarly marked out. On the one hand, this appears to be a failure of 
legal imagination to take advantage of an additional defensive claim. On the other 
hand, it seems to indicate an uncritical assumption that the category “Caucasian” and 
“individual” in the first claim were co-extensive and that only non-White races 
counted as distinct sub-groups to be marked out as the basis for defensive claims. 
 
Perhaps most incongruous, yet illustrative of the strategic reification of race and 
ethnicity in the context of biotechnology patents, are the few applications, such as one 
for “Manganese superoxide dismutase gene polymorphism for predicting cancer 
susceptibility”, filed 8 April 2004, that invoke “Hispanic” as a genetic term.48 This 
particular application is distinctive both for its foregrounding of ethnicity in its first 
claim, and for its genetic reification of the ethnic category “Hispanic” which generally 
does not have the same pronounced history of reification as racial categories such as 
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“African” or “Asian.” Indeed, as an ethnic category, Hispanic is so diffuse and diverse 
that it does not even have the purported link to continental ancestry that sometimes 
undergirds justifications for using racial categories as surrogates for ancestral descent 
populations. Using Hispanic as a catch-all genetic category risks both reifying 
ethnicity and providing misleading and conceptually muddled scientific data. 
 
As the chart of race-specific patents indicates, there are many references to 
“Caucasians”. Several of these involve disease conditions and so may be understood 
implicitly to pathologize Whiteness as well. Upon closer examination, however, two 
qualifying characteristics mark “Whiteness” in several of these patents as neither 
deviant nor pathological. First are situations where the overwhelming majority of test 
subjects in the studies underlying a patent were White and so Whiteness becomes a 
sort of default category for an additional defensive claim. Second are the patents that 
mark Whiteness out of concern for a heightened efficacy of a potential medical 
treatment. 
 
In a patent application for “Genetic diagnosis of depression,” filed 8 July 2004, the 
first claim specifies “a method of identifying individuals predisposed to major 
depressive disorder”.49 Its race-specific Claim 4 specifies “The method of claim 1, 
wherein said subject is Caucasian.” At first blush the patent might seem to be 
pathologizing Whiteness by associating it with depression. Upon closer examination, 
however, it turns out that the studies underlying the invention were conducted in an 
exclusively “Caucasian” population (which the patent defines rather broadly as 
members of “the white race consisting of individuals of European, north African, or 
southwest Asian ancestry”). The clinical studies alluded to in the body of the patent 
did not show anything distinctive about Caucasians that would identify them as 
having race-specific markers for depression that differentiated them from any other 
race. The invocation of race here does not logically follow from the clinical evidence. 
Rather, following the commercial logic of patent law, rather than science, the patent 
drafters have employed race defensively to protect against possible challenges to the 
patent. Such strategic reification of race has been facilitated as race has come more 
commonly to be understood and accepted as a legitimate and salient category both in 
genetic research and in patent strategy. Having learned to “see” race as relevant to 
patent protection, the inventors invoked the category “Caucasian” because it was the 
only available race they could extract from their data. 
 
A patent for a “Peptide-based vaccine for influenza”, issued 25 May 2004, 
exemplifies the use of Whiteness as a target for improved therapy.50 Its first claim 
refers to “the NP380-393 epitope51 according to SEQ ID NO: 5 that are the most 
prevalent HLA molecules in a Caucasian human population.” As elaborated in the 
“Description of the Invention” section, the patent specifies that the vaccine will 
change “according to the population type” and asserts that “the CTL influenza 
epitopes are different in the Caucasian, the Asia- or Africa-originated population 
[sic]”. It does not define these populations, but it refers to them elsewhere as 
“Caucasian and non-Caucasian”, clearly privileging Caucasian as the norm. And 
indeed, Caucasian is the only race specified in the legally enforceable Claims section, 
making it a target of the invention. 
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Similarly, the patent application for a “Mixture of peptides derived from e6 and/or e7 
papillomavirus proteins and uses thereof”, filed 2 November 2004, characterizes the 
invention of terms of an allele with a particular frequency in the Caucasian 
population.52 Unlike the BiDil patent, this application does not use Caucasian as a 
term that deviates from a particular norm or has a pathological gene variation, but 
rather as a population with a gene variation that will enable it to take advantage of the 
proposed invention. Here Caucasian genes are positive and empowering. 
 
One reason for this, of course, is that Caucasian genes are where the money is. This is 
made abundantly clear in a patent application for “Methods for obtaining and using 
haplotype data”, filed 21 December 2001 by scientists from Genaissance 
Pharmaceuticals,53 a biotech company that describes itself as “a world leader in the 
discovery and use of human gene variation for the development of a new generation 
of DNA-based diagnostic and therapeutic products”.54 The market model of 
Genaissance is built around capitalizing on human genetic variation. It has a stake in 
finding population-specific genetic differences. In developing new products, 
Genaissance mines existing federally maintained genetic data-bases as an exploitable 
resource – a resource that already employs a myriad of population categories that are 
ripe for being conflated with the OMB 15 social categories of race. 
 
Genaissance’s application also explicitly capitalizes on the type of data being 
produced by the federally sponsored HapMap project. This application begins with a 
broad claim to “A method of generating a haplotype database for a population”. It 
goes on in Claim 8 to specify that the reference population may include an “ethnic 
population”, thereby directly connecting ethnicity to genetics. In the body of the 
patent it becomes clear that Genaisance is using the terms race and ethnicity more or 
less interchangeably. Thus, for example, it notes that “The invention may also be used 
to link variations in DNA to personal identity and racial or ethnic background”. In 
describing the “Field of the Invention” after the claims section, the patent marks 
pharmacogenomic uses as primary, noting that genetic haplotype information can be 
used “to predict an individual’s susceptibility to a particular disease and/or their 
response to a particular drug”. Here the patent invokes the pharmacogenomic 
promised land of personalized medicine, but the invention largely depends on using 
racial and ethnic categories as proxies for genetic variation precisely because the 
practical reality of widespread use of truly individualized therapy remains far in the 
future. 
 
To this point, the patent uses race and ethnicity broadly, without singling out any 
particular group. Strikingly, however, in the “Detailed Description of the Invention”, 
the patent elaborates on one particular embodiment of the invention declaring that, 
 
Analysis of the candidate gene(s) (or other loci) requires an approximate knowledge 
of what haplotypes exist for the candidate gene(s) (or other loci) and of their 
frequencies in the general population. To do this, a reference population is recruited, 
or cells from individuals of known ethnic origin are obtained from a public or private 
source. The population preferably covers the major ethnogeographic groups in the 
U.S., European, and Far Eastern pharmaceutical markets. [Emphasis added.] 
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This description weaves ethnicity into the concept of a “reference population”. This is 
essential to a marketing strategy that exploits race in the gap between current realities 
and the promised future benefits of individualized pharmacogenomic therapies. 
Secondly, the description, whether intentionally or not, is a brazen declaration that 
ethnicity only matters where markets matter – the U.S., Europe and the Far East. 
Africa, South America, the Middle East and South Asia apparently are irrelevant. The 
patent invokes ethnicity not solely as a short cut to finding genetic correlations with 
particular population groups, but also, and inextricably, as a basis for developing 
drugs for major markets. Ethnicity here becomes a function not only of genes, but of 




In the cases of BiDil and the Myriad BRCA2 test, racialized patents have played a 
central role in the marketing strategy for the product. Both involve technologies that 
were already available and in use. Adding race to the patents did not change the 
technology so much as it provided an added incentive to market and extend monopoly 
control for the product. This moves beyond the use of race to defend a patent against 
potential challenges to an affirmative projection of race as a central component of 
product development and marketing. In the case of BiDil, race also unmistakably 
added publicity value to the product. A good deal of the publicity both produced and 
was produced by social understandings that reified race as genetic. 
 
The striking rise of racialized biotechnology patents indicates that cases such as BiDil 
are paving the way for a new proliferation of patents and drug approvals that are 
producing new and highly problematic understandings of race as genetic. BiDil 
obtained its commodity value from the rebiologization of race in the regulatory 
process. Additional racial patents, for products not yet as prominent as BiDil, have 
secured the imprimatur of the state for using race as a genetic category. Like more 
traditional extractive industries, biotechnology corporations are mining the raw 
material of race as a social category and using the patent process to refine it into a 
natural construct that lends legal utility and novelty to their inventions. The patents 
are in place and proliferating, ready to be invoked to protect a product or extend a 
market. Genetic race literally is becoming a commodity as race-specific patents allow 
biotechnology corporations to raise venture capital and develop marketing strategies 
that present a reified conception of race as genetic to doctors, regulators, and the 
public at large. 
 
 
                                                 
1 This article is reprinted by permission of Rutgers University Press from Revisiting Race in a Genomic 
Age. B.A. Koenig, S.S.-J. Lee and S.S. Richardson, eds. Copyright © 2008 by Rutgers, The State 
University. Work on this article was supported by the Ethical, Legal and Social Implications Research 
Program, National Human Genome Institute (Grant number R03-HG004034-01A1) 
2 Hamline University School of Law, St. Paul, Minnesota, USA jkahn01@hamline.edu 
3 See, for example, Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95 (S.D.N.Y. 1911). 
4 J. Kahn. What’s the use? Law and authority in patenting human genetic material. Stanford Law & 
Policy Review 2003; 14: 417-444. 
5 66 Federal Register 1093. 
6 S. Jasanoff. The life sciences and the rule of law. Journal of Molecular Biology 2002; 319: 891-899, 
p.895. 
            Genomics, Society and Policy 
  2008  2008, Vol.4, No.3, pp.46-63 
 
_____________  16 
Genomics, Society and Policy, Vol.4, No.3 (2008) ISSN: 1746-5354 
© ESRC Genomics Network. 
                                                                                                                                            
7 US Patent and Trademark Office. 2004. Manual of Patent Examining Procedure, § 1504.01(e). 
http://www.uspto.gov/web/offices/pac/mpep/documents/1500_1504_01_e.htm#sect1504.01e  
8 In the interests of economy and manageable syntax, in the remainder of the paper I will often refer 
only to “race” when speaking generally of racial and ethnic categories. I am assuming both to be 
socially constructed categories that nonetheless have come to have biological implications as they play 
out in real world biomedical contexts. I will use the terms “race” and/or “ethnic” when referring to 
specifically marked groups. Thus, for example, the U.S. Census codes “White” or “Asian” as racial 
categories and “Hispanic” or “Latino” as ethnic categories. 
9 National Institutes of Health. 2001. NIH Policy and guidelines on the inclusion of women and 
minorities as subjects in clinical research. Available at 
http://grants2.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. 
10 Food and Drug Modernization Act of 1997, 111 Stat. 2296; US Food and Drug Administration. 
1999. Population pharmacokinetics. Available at 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072
137.pdf  
11 US Food and Drug Administration. 2005. Guidance for industry: collection of race and ethnicity 
data in clinical trials. Available at 
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126396.pdf. 
12 US Office of Management and Budget. 1997. Revisions to the standards for the classification of 
Federal data on race and ethnicity. Available at 
http://www.whitehouse.gov/omb/fedreg/ombdir15.html. 
13 Ibid 
14 M. Omi. Racial identity and the State: The dilemmas of classification. Law & Inequality Journal 
1997; 15: 7-24, p.21. 
15 Ibid, p.7 
16 National Center for Biotechnology Information. 2005. GenBank Overview. Available at 
http://www.ncbi.nlm.nih.gov/Genbank/index.html. 
17 G. Bowker & S.L. Star. 1999. Sorting Things Out: Classification and Its Consequences. Cambridge: 
MIT: 5-6. 
18 T. Duster. 1990. Backdoor to Eugenics. New York: Routledge; M. Foster. 2002. Ethical issues in 
developing a haplotype map with socially-defined populations. Available at  
http://www.genome.gov/10001683 ; M. Lock. Genetic diversity and the politics of difference. 
Chicago-Kent Law Review 1999; 75: 83-112; J. Marks. 1995. Human biodiversity: Genes, race and 
history. New York: Aldine De Gruyter. 
19 Bowker & Star, op. cit. note 17, p.196. 
20 US Food and Drug Administration. FDA Approves BiDil Heart Failure Drug for Black Patients. 
FDA News 2005; 23 June. 
21 J. Kahn. How a drug becomes ‘ethnic’: Law, commerce, and the production of racial categories in 
medicine. Yale Journal of Health Policy, Law & Ethics 2004; 4: 1-46. 
22 Ibid; Kahn, op. cit. note 4; J. Kahn. 2005. January/February. ‘Ethnic’ drugs. The Hastings Center 
Report 2005; 35(1); S.S.-J. Lee. 2008. Racial Realism and the Discourse of Responsibility for Health 
Disparities in a Genomic Age. In Revisiting Race in a Genomic Age. B.A. Koenig, S.S.-J. Lee and S.S. 
Richardson, eds. Rutgers University Press : 342-358. 
23 Kahn, op. cit. note 21. 
24 A. Taylor et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. New 
England Journal of Medicine 2004; 351: 2049-2057. 
25 Kahn, op. cit. note 21; Kahn 2005, op. cit. note 22. 
26 G. Petsko. Color Blind. Genome Biology 2004; 5: 119; T. Rahemtulla and R. Bhopal. 
Pharmacogenetics and ethnically targeted therapies. British Medical Journal 2005; 300: 1036-37; R. 
Carlson. The case of BiDil: A policy commentary on race and genetics. Health Affairs 2005; 11 
October. Available at http://content.healthaffairs.org/cgi/content/abstract/hlthaff.w5.464v1. 
27 U.S. Patent No. 6,465,463 
28 Kahn, op. cit. note 21; P. Sankar and J. Kahn. 2005 BiDil: Race Medicine or Race Marketing? 
Health Affairs 2005; 11 October. Available at 
http://content.healthaffairs.org/cgi/content/full/hlthaff.w5.455/DC1. 
29 Taylor et al, op. cit. note 24. 
30 M. Herper. Race-based medicine arrives. Forbes 2005; 10 May. Available at 
http://www.forbes.com/2005/05/10/cx_mh_0509racemedicine.html. 
            Genomics, Society and Policy 
  2008  2008, Vol.4, No.3, pp.46-63 
 
_____________  17 
Genomics, Society and Policy, Vol.4, No.3 (2008) ISSN: 1746-5354 
© ESRC Genomics Network. 
                                                                                                                                            
31 S.K. Tate and D.B. Goldstein. 2008. Will Tomorrow’s Medicines Work for Everyone? In Revisiting 
Race in a Genomic Age. B.A. Koenig, S.S.-J. Lee and S.S. Richardson, eds. Rutgers University Press : 
102-128. 
32 G. Kienzel. BRCA2 Patent Upheld. The Scientist 2005; 1 July. Available at http://www.the-
scientist.com/news/20050701/01/. 
33 M. Gessen. Jewish guinea pigs. Slate.com 2005; 26 July. Available at 
http://slate.msn.com/id/2123397. 
34 Royal Society. 2005. Personalised medicines: Hopes and realities. Royal Society: London. 
35 D. Chisum et al. 2001. Principles of Patent Law (2nd ed.). New York: Foundation Press: 2 (citing 35 
U.S.C. § 154) 
36 G. Elliott. A brief guide to understanding patentability and the meaning of patents. Academic 
Medicine 2002; 77: 1309-1314. 
37 Diamond .v Chakrabarty. 477 U.S. 303 (1980). 
38 Kahn, op. cit. note 4. 
39 US Food and Drug Administration. 2003. Guidance for Industry: Pharmacogenomic Data 
Submissions. Available at 
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126957.pdf; FDA, op. cit. note 
11. 
40 Issued patents have been formally approved by the PTO. Patent applications are currently pending 
before the PTO for review. Under new policies applications are made available to the public 18 months 
after their initial filing while still pending review.  
41 “Metes and bounds” is a legal description of a parcel of land that begins at a well-marked point and 
follows the boundaries, using directions and distances around the tract, back to the place of beginning. 
42 The results are from searches of the US PTO patent data-base conducted between 8/25/05 and 
9/15/05, using the web-based search engine available at www.uspto.gov. The search terms used 
included: Race, Racial, Ethnic, Ethnicity, Caucasian, Caucasoid, African, African-American, Negro, 
Negroid, Asian, Oriental, Mongoloid, Hispanic, Latino, Native American, Alaska Native, Pacific 
Islander. The terms “black” and “white” alone were too broad to be useful and so were qualified with 
the additional terms of “gene” or “genetic” or “nucleotide.” 
43 This is an admittedly subjective basis for sorting the patents. The categorization of patents that imply 
or assert a significant genetic component to race or ethnicity is meant to exclude those patents that use 
racial/ethnic categories as one or more of a longer list of general demographic characteristics, usually 
employed for information organization, rather than for identifying or treating a particular physiological 
state. The categorization is meant to include those patents that use racial/ethnic categories as a basis for 
asserting a distinctive prevalence or etiology for a physiological condition, genetic variation, and/or 
drug response. 
44 U.S. Patent Application No. 20030215819 
45 U.S. Patent Application No. 20040126794. 
46 R. Bowser. Racial Profiling in Health Care: An Institutional Analysis of Medical Treatment 
Disparities. Michigan Journal of Race & Law 2001; 7: 79. 
47 U.S. Patent Application No. 20030170651 
48 U.S. Patent Application No. 20040067519 
49 U.S. Patent Application No. 20040132062 
50 U.S. Patent No. 6,740,325 
51 An epitope is a single antigenic site on a protein against which an antibody reacts. 
52 U.S. Patent Application No. 20040170644 
53 Genaissance. No date. Overview. http://www.genaissance.com/aboutus/home.html (retrieved 7 
November 2005) 
54 U.S. Patent Application No. 20040267458 
